Literature DB >> 1902329

Effective induction of anti-phospholipid and anticoagulant antibodies in normal mouse.

K Igarashi1, M Umeda, S Tokita, K S Nam, K Inoue.   

Abstract

Anti-phosphatidylserine (anti-PS) antibodies of the IgG isotype in the serum of BALB/c mouse were effectively induced by the intrasplenic immunization of phosphatidylserine (PS), while only a slight increase of the titer was observed when the antigen was injected intravenously. The serum antibodies cross-reacted extensively with other acidic phospholipids, but not with phosphatidylcholine (PC). A remarkable frequency of anti-PS mAbs of the IgG isotype was also observed even when mAbs were produced 10 days after the intrasplenic injection of the antigen. Reactivities of the fifteen mAbs, which had been established from BALB/c mice by the intrasplenic immunization with PS, were further analyzed. Among the fifteen mAbs examined, thirteen cross-reacted with ssDNA and two bound to dsDNA. Seven mAbs had lupus anticoagulant activity and four bound to cultured human umbilical vein endothelial cells (HUVECs). No significant correlation was found among phospholipid specificities, anti-DNA, anticoagulant, and HUVEC binding activities. One mAb of the IgG2b subclass, named PSG3, which had been produced 10 days after the immunization, was shown to have a strong lupus anticoagulant, dsDNA binding, and HUVEC binding activities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902329     DOI: 10.1016/0049-3848(91)90240-w

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone.

Authors:  S S Pierangeli; E N Harris
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

2.  Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).

Authors:  A E Gharavi; L R Sammaritano; J Wen; K B Elkon
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.